KDNY - Chinook Therapeutics, Inc. Stock Price and Quote

KDNY | Chinook Therapeutics, Inc. | [NASD]

Index	-	P/E	-	EPS (ttm)	-3.19	Insider Own	1.80%	Shs Outstand	70.70M	Perf Week	9.63%
Market Cap	1.50B	Forward P/E	-	EPS next Y	-3.45	Insider Trans	-42.99%	Shs Float	62.26M	Perf Month	21.19%
Income	-216.40M	PEG	-	EPS next Q	-0.82	Inst Own	98.20%	Short Float / Ratio	7.02% / 6.39	Perf Quarter	11.14%
Sales	5.30M	P/S	283.08	EPS this Y	-29.30%	Inst Trans	5.20%	Short Interest	4.37M	Perf Half Y	21.74%
Book/sh	5.83	P/B	4.16	EPS next Y	-6.80%	ROA	-37.50%	Target Price	36.00	Perf Year	74.71%
Cash/sh	5.66	P/C	4.28	EPS next 5Y	9.00%	ROE	-47.10%	52W Range	13.84 - 27.44	Perf YTD	-7.44%
Dividend	-	P/FCF	-	EPS past 5Y	13.60%	ROI	-42.90%	52W High	-11.63%	Beta	0.14
Dividend %	-	Quick Ratio	7.00	Sales past 5Y	-18.70%	Gross Margin	-	52W Low	75.22%	ATR	1.19
Employees	214	Current Ratio	7.00	Sales Q/Q	-33.30%	Oper. Margin	-	RSI (14)	64.44	Volatility	4.95% 5.73%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-56.70%	Profit Margin	-	Rel Volume	0.80	Prev Close	23.31
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	683.52K	Price	24.25
Recom	1.50	SMA20	12.94%	SMA50	11.76%	SMA200	8.56%	Volume	555,191	Change	4.03%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-06-23	Initiated	Piper Sandler	Overweight	$41
Mar-01-23	Initiated	Guggenheim	Buy	$43
Dec-05-22	Initiated	Wells Fargo	Overweight	$30
Jun-28-22	Initiated	Stifel	Buy	$30
Jan-06-21	Initiated	Wedbush	Outperform	$28
Dec-10-20	Initiated	Cantor Fitzgerald	Overweight	$31
Nov-16-20	Initiated	H.C. Wainwright	Buy	$28
Nov-02-20	Initiated	Evercore ISI	Outperform	$32
Oct-20-20	Upgrade	Oppenheimer	Perform → Outperform	$25

May-16-23 08:00AM	Chinook Therapeutics Announces Partnership with Ionis to Develop Antisense Therapy for Rare, Severe Chronic Kidney Disease (GlobeNewswire)
May-09-23 04:00PM	Chinook Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Updates (GlobeNewswire)
May-05-23 04:05PM	Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
04:00PM	Chinook Therapeutics Announces Upcoming Presentations and Investor Conference Call at the 60th European Renal Association (ERA) Congress (GlobeNewswire)
Apr-27-23 04:00PM	Chinook Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) -6.79%
08:56AM	Loading…
Apr-23-23 08:56AM	TipRanks Perfect 10 List: These 2 Top-Rated Stocks Could Be Long-Term Winners (TipRanks)
Apr-13-23 08:00AM	Chinook Therapeutics Announces the Appointment of Robert W. Azelby to its Board of Directors (GlobeNewswire)
Apr-11-23 04:00PM	Chinook Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) -5.65%
08:00AM	Chinook Therapeutics Announces Voluntary Pause in Dosing of CHK-336 in Ongoing Phase 1 Clinical Trial in Healthy Volunteers (GlobeNewswire)
Apr-07-23 04:00PM	Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-28-23 04:00PM	Chinook Therapeutics to Present at the Guggenheim Healthcare Talks \| Genomic Medicines and Rare Disease Days (GlobeNewswire)
Mar-23-23 08:00AM	Chinook Therapeutics Announces Upcoming Presentations at ISN World Congress of Nephrology 2023 (GlobeNewswire)
Mar-07-23 04:00PM	Chinook Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference (GlobeNewswire)
Mar-03-23 04:00PM	Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-28-23 08:00AM	Chinook Therapeutics Announces Upcoming Presentations at the 5th Chronic Kidney Disease Drug Development Summit (GlobeNewswire)
04:00PM	Loading…
Feb-27-23 04:00PM	Chinook Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates (GlobeNewswire)
Feb-15-23 08:00AM	Chinook Therapeutics Announces the Appointment of Andrew Oxtoby as Chief Commercial Officer (GlobeNewswire) -5.77%
Feb-07-23 04:05PM	Chinook Therapeutics to Present at SVB Securities Global Biopharma Conference (GlobeNewswire)
Feb-06-23 04:05PM	Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-03-23 04:00PM	Chinook Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-22-22 04:05PM	Chinook Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-10-22 04:00PM	Chinook Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results (GlobeNewswire)
Nov-04-22 10:00AM	Chinook Therapeutics Presents Updated Data from BION-1301 Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) and CHK-336 Preclinical Efficacy Data at the American Society of Nephrology (ASN) Kidney Week 2022 (GlobeNewswire)
Nov-03-22 10:00AM	Chinook Therapeutics Presents Updated Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Cohort, Preclinical Atrasentan Research and Ongoing Clinical Trials at the American Society of Nephrology (ASN) Kidney Week 2022 (GlobeNewswire)
Nov-02-22 04:00PM	Chinook Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Oct-14-22 08:00AM	Chinook Therapeutics Announces Upcoming Presentations and Investor Conference Call at the American Society of Nephrology (ASN) Kidney Week 2022 (GlobeNewswire)
Sep-01-22 04:05PM	Chinook Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-12-22 06:17AM	Need To Know: The Consensus Just Cut Its Chinook Therapeutics, Inc. (NASDAQ:KDNY) Estimates For 2022 (Simply Wall St.)
Aug-08-22 04:00PM	Chinook Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results (GlobeNewswire)
Aug-04-22 04:05PM	Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.76%
04:05PM	Loading…
Aug-02-22 04:05PM	Chinook Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Jul-05-22 04:05PM	Chinook Therapeutics to Present at the William Blair Biotech Focus Conference 2022 (GlobeNewswire)
08:00AM	Chinook Therapeutics Receives Orphan Drug Designation from European Commission for BION-1301 for Treatment of Primary IgA Nephropathy (IgAN) (GlobeNewswire)
Jun-28-22 06:14AM	Could The Chinook Therapeutics, Inc. (NASDAQ:KDNY) Ownership Structure Tell Us Something Useful? (Simply Wall St.)
May-29-22 08:26AM	Trade Alert: The President Of Chinook Therapeutics, Inc. (NASDAQ:KDNY), Eric Dobmeier, Has Just Spent US$65k Buying 2.5% More Shares (Simply Wall St.)
May-24-22 09:57PM	Chinook Therapeutics Announces Pricing of a $105 Million Public Offering (GlobeNewswire)
04:02PM	Chinook Therapeutics Announces Proposed Public Offering (GlobeNewswire)
May-20-22 10:25AM	Chinook Therapeutics Presents Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Cohort and Evotec Collaboration at the 59th European Renal Association (ERA) Congress 2022 (GlobeNewswire) +8.38%
May-19-22 02:05AM	Chinook Therapeutics Presents Updated Data from BION-1301 Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) and from Atrasentan Preclinical Mechanism of Action Studies at the 59th European Renal Association (ERA) Congress 2022 (GlobeNewswire) +10.01%
May-12-22 04:20PM	Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
04:00PM	Chinook Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results (GlobeNewswire)
May-03-22 01:26PM	Chinook Therapeutics (NASDAQ:KDNY) shareholders have endured a 16% loss from investing in the stock a year ago (Simply Wall St.)
May-02-22 10:25AM	Chinook Therapeutics Announces Upcoming Data Presentations and Investor Conference Call at the 59th European Renal Association (ERA) Congress (GlobeNewswire) +5.75%
Apr-25-22 04:05PM	Chinook Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference (GlobeNewswire)
Apr-12-22 08:00AM	Chinook Therapeutics Announces Initiation of Phase 1 Healthy Volunteer Trial of CHK-336, a First-in-Class LDHA Inhibitor to Treat Hyperoxalurias (GlobeNewswire)
Apr-05-22 04:05PM	Chinook Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference (GlobeNewswire) -10.98%
08:00AM	Chinook Therapeutics, IgA Nephropathy Foundation and Komodo Health Collaborate to Provide Nephrologists with Support and Information to Help Reduce Barriers to Diagnosis and Care (GlobeNewswire)
Mar-21-22 08:15AM	Chinook Therapeutics Announces Appointment of Dr. Mahesh Krishnan to its Board of Directors (GlobeNewswire)
Mar-17-22 04:00PM	Chinook Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire)
Mar-08-22 04:05PM	Chinook Therapeutics to Present at Oppenheimers 32nd Annual Healthcare Conference (GlobeNewswire)
Feb-22-22 08:15AM	Chinook Therapeutics Announces Upcoming Presentations at 4th Annual Chronic Kidney Disease Drug Development Summit (GlobeNewswire)
Feb-18-22 08:15AM	Chinook Therapeutics Announces Upcoming Encore Presentations at ISN World Congress of Nephrology 2022 (GlobeNewswire)
Feb-09-22 04:05PM	Chinook Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference (GlobeNewswire) +5.90%
Feb-07-22 07:38AM	Chinook Therapeutics, Inc. (NASDAQ:KDNY) insider upped their holding by 10% earlier this year (Simply Wall St.)
Feb-04-22 04:05PM	Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-04-22 08:15AM	Chinook Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Dec-14-21 08:15AM	Chinook Therapeutics Receives Orphan Drug Designation from European Commission for Atrasentan for Treatment of Primary IgA Nephropathy (GlobeNewswire) -5.15%
Dec-07-21 06:59AM	What Type Of Shareholders Own The Most Number of Chinook Therapeutics, Inc. (NASDAQ:KDNY) Shares? (Simply Wall St.)
Nov-30-21 08:00AM	Chinook Therapeutics Announces Formation of SanReno Therapeutics, a Joint Venture to Develop Kidney Disease Therapies in China (GlobeNewswire)
Nov-22-21 08:18PM	Strong Insider Buying Puts These 3 Stocks in Focus (TipRanks)
Nov-17-21 04:05PM	Chinook Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-15-21 04:05PM	Chinook Therapeutics Announces Closing of $183.5 Million Public Offering, Including Full Exercise of Underwriters Option to Purchase Additional Shares (GlobeNewswire)
Nov-09-21 08:36PM	Chinook Therapeutics Announces Pricing of an Upsized $160 Million Public Offering (GlobeNewswire)
Nov-08-21 04:01PM	Chinook Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire) -11.09%
08:00AM	Chinook Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results (GlobeNewswire)
Nov-04-21 01:05PM	Chinook Therapeutics Presents Data from BION-1301 Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) and Atrasentan Program at the American Society of Nephrology (ASN) Kidney Week 2021 (GlobeNewswire) +8.99%
Oct-15-21 04:05PM	Chinook Therapeutics Announces Upcoming Data Presentations and Investor Conference Call During the American Society of Nephrology (ASN) Kidney Week 2021 (GlobeNewswire)
Oct-06-21 10:02AM	Investors in Chinook Therapeutics (NASDAQ:KDNY) have unfortunately lost 15% over the last year (Simply Wall St.)
Sep-20-21 08:15AM	Chinook Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Sep-02-21 04:05PM	Chinook Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-25-21 11:38AM	Insiders Go Big on These 3 Hot Stocks (TipRanks)
Aug-12-21 04:05PM	Chinook Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results (GlobeNewswire)
Jul-12-21 04:05PM	Chinook Therapeutics to Present at the William Blair Biotech Focus Conference 2021 (GlobeNewswire)
Jul-07-21 04:05PM	Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-06-21 05:21AM	Have Insiders Been Buying Chinook Therapeutics, Inc. (NASDAQ:KDNY) Shares? (Simply Wall St.)
Jun-09-21 08:15AM	Chinook Therapeutics Announces Promotions of Tom Frohlich to Chief Operating Officer and Andrew King, D.V.M, Ph.D., to Chief Scientific Officer (GlobeNewswire) -5.08%
Jun-08-21 08:15AM	Chinook Therapeutics Presents BION-1301 Interim Phase 1/2 Data in Patients with IgA Nephropathy (IgAN) at the 58th ERA-EDTA Virtual Congress (GlobeNewswire) +5.17%
May-25-21 04:05PM	Chinook Therapeutics to Host Conference Call and Webcast Featuring BION-1301 Data Presented at the 58th ERA-EDTA Congress (GlobeNewswire)
May-13-21 04:05PM	Chinook Therapeutics to Present at the 2021 RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
May-12-21 04:05PM	Chinook Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results (GlobeNewswire)
May-04-21 04:15PM	Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.48%
Apr-15-21 08:15AM	Chinook Therapeutics Presents Data During the ISN World Congress of Nephrology 2021 (GlobeNewswire) +10.43%
Apr-08-21 04:30PM	Chinook Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Apr-07-21 04:05PM	Chinook Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results (GlobeNewswire)
08:15AM	Chinook Therapeutics Announces First Patient Dosed in Phase 2 AFFINITY Basket Study of Atrasentan in Proteinuric Glomerular Diseases (GlobeNewswire)
Apr-05-21 08:15AM	Chinook Therapeutics Announces Update on Non-Renal Legacy Programs from Aduro Biotech Merger (GlobeNewswire)
Apr-01-21 04:15PM	Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-30-21 04:26PM	Chinook Therapeutics Announces Upcoming Data Presentations at ISN World Congress of Nephrology 2021 and 58th ERA-EDTA Congress (GlobeNewswire) +6.96%
Mar-16-21 08:15AM	Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 ALIGN Study of Atrasentan for Patients with IgA Nephropathy (GlobeNewswire) -7.20%
Mar-02-21 04:15PM	Chinook Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Mar-01-21 08:15AM	Chinook Therapeutics and Evotec Announce Strategic Collaboration to Discover and Develop Novel Precision Medicines for Chronic Kidney Diseases (GlobeNewswire)
Feb-23-21 08:15AM	Chinook Therapeutics to Present at 3rd Annual Chronic Kidney Disease Drug Development (CKD3) Summit (GlobeNewswire)
Feb-17-21 04:15PM	Chinook Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference (GlobeNewswire) +5.34%
Feb-02-21 08:15AM	Chinook Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for CHK-336 for Treatment of Primary Hyperoxaluria (GlobeNewswire)
Jan-07-21 03:01AM	Who Has Been Buying Chinook Therapeutics, Inc. (NASDAQ:KDNY) Shares? (Simply Wall St.)
Jan-04-21 08:15AM	Chinook Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Dec-08-20 08:15AM	Chinook Therapeutics Announces License Agreement with Morehouse School of Medicine for Development of Therapies in Kidney Diseases Disproportionately Affecting African Americans and Underserved Communities (GlobeNewswire)
Nov-30-20 04:15PM	Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-18-20 04:15PM	Chinook Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-10-20 08:15AM	Chinook Therapeutics Announces Appointment of Eric Bjerkholt as Chief Financial Officer (GlobeNewswire)

Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
DOBMEIER ERIC	President, CEO	Apr 24	Option Exercise	0.42	25,000	10,500	326,138	Apr 26 05:19 PM
DOBMEIER ERIC	President, CEO	Apr 24	Sale	21.58	23,800	513,528	302,338	Apr 26 05:19 PM
Jerel Davis	Director	Apr 17	Sale	20.75	295,808	6,138,223	443,713	Apr 19 05:58 PM
Krishnan Mahesh	Director	Apr 04	Sale	23.01	924	21,261	1,275	Apr 04 09:14 PM
King Andrew James	Chief Scientific Officer	Apr 03	Option Exercise	0.35	2,500	875	21,992	Apr 05 04:43 PM
King Andrew James	Chief Scientific Officer	Apr 03	Sale	23.34	5,000	116,718	16,992	Apr 05 04:43 PM
Jerel Davis	Director	Mar 01	Sale	22.75	400,000	9,100,000	210,996	Mar 03 04:13 PM
DOBMEIER ERIC	President, CEO	Feb 10	Sale	23.75	8,097	192,292	301,138	Feb 15 04:40 PM
Frohlich Tom	Chief Operating Officer	Feb 10	Sale	23.75	3,700	87,869	150,777	Feb 15 04:40 PM
King Andrew James	Chief Scientific Officer	Feb 10	Sale	23.75	2,392	56,806	19,492	Feb 15 04:39 PM
BJERKHOLT ERIC	Chief Financial Officer	Feb 10	Sale	23.75	857	20,352	38,867	Feb 15 04:41 PM
DOBMEIER ERIC	President, CEO	Jan 31	Sale	24.68	7,688	189,757	288,987	Feb 01 08:32 PM
Frohlich Tom	Chief Operating Officer	Jan 31	Sale	24.68	4,566	112,700	147,674	Feb 02 06:15 PM
King Andrew James	Chief Scientific Officer	Jan 31	Sale	24.68	3,244	80,069	15,081	Feb 02 06:13 PM
BJERKHOLT ERIC	Chief Financial Officer	Jan 31	Sale	24.68	2,891	71,357	37,289	Feb 02 06:14 PM
DOBMEIER ERIC	President, CEO	Jan 30	Option Exercise	0.42	25,000	10,500	296,676	Feb 01 08:32 PM
DOBMEIER ERIC	President, CEO	Jan 30	Sale	24.54	25,000	613,612	271,676	Feb 01 08:32 PM
King Andrew James	Chief Scientific Officer	Jan 03	Option Exercise	0.35	7,500	2,625	19,992	Jan 04 07:44 PM
King Andrew James	Chief Scientific Officer	Jan 03	Sale	25.82	10,000	258,183	9,992	Jan 04 07:44 PM
DOBMEIER ERIC	President, CEO	Dec 14	Option Exercise	0.35	30,000	10,500	271,676	Dec 15 04:27 PM
Frohlich Tom	Chief Operating Officer	Dec 13	Option Exercise	0.42	10,000	4,200	153,907	Dec 15 04:28 PM
Frohlich Tom	Chief Operating Officer	Dec 13	Sale	25.00	10,000	250,005	143,907	Dec 15 04:28 PM
DOBMEIER ERIC	President, CEO	Dec 01	Option Exercise	0.42	60,000	25,200	271,676	Dec 02 04:26 PM
DOBMEIER ERIC	President, CEO	Dec 01	Sale	22.31	30,000	669,351	241,676	Dec 02 04:26 PM
BJERKHOLT ERIC	Chief Financial Officer	Dec 01	Sale	22.29	5,770	128,602	32,847	Dec 02 04:25 PM
Frohlich Tom	Chief Operating Officer	Nov 07	Option Exercise	0.42	10,000	4,200	153,907	Nov 09 04:21 PM
Frohlich Tom	Chief Operating Officer	Nov 07	Sale	22.16	10,000	221,642	143,907	Nov 09 04:21 PM
Frohlich Tom	Chief Operating Officer	Oct 06	Sale	19.69	7,360	144,933	143,907	Oct 11 04:33 PM
King Andrew James	Chief Scientific Officer	Oct 06	Sale	19.69	3,557	70,044	12,492	Oct 11 04:32 PM
Thomas Dolca	Director	Sep 02	Buy	21.22	10,000	212,194	10,000	Sep 06 04:35 PM
King Andrew James	Chief Scientific Officer	Aug 04	Option Exercise	0.35	5,000	1,750	10,897	Aug 05 05:09 PM
King Andrew James	Chief Scientific Officer	Aug 04	Sale	20.00	5,000	100,000	5,897	Aug 05 05:09 PM
King Andrew James	Chief Scientific Officer	Jul 11	Option Exercise	0.35	5,000	1,750	10,897	Jul 13 04:11 PM
King Andrew James	Chief Scientific Officer	Jul 11	Sale	18.09	5,000	90,468	5,897	Jul 13 04:11 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience